All Metrics
DGX Valuation Metrics
DGX Stock Price Metrics
DGX Dividend Metrics
DGX Growth Rate Metrics
DGX Discounted Cash Flow Metrics
| Fair Value Price | $224.55 |
| Margin of Safety | 8.88% |
DGX Revenue Metrics
DGX PE Ratio Metrics
| PE Ratio | 22.79 |
| PE Ratio Avg TTM | 21.73 |
| PE Ratio Avg 3Y | 20.67 |
| Current VS TTM Avg | +4.87% |
| Current VS 3Y Avg | +10.26% |
| Current VS 5Y Avg | +33.09% |
DGX PS Ratio Metrics
| PS Ratio | 2.05 |
| PS Ratio Avg TTM | 1.94 |
| PS Ratio Avg 3Y | 1.81 |
| Current VS TTM Avg | +5.90% |
| Current VS 3Y Avg | +13.35% |
| Current VS 5Y Avg | +18.14% |
DGX PB Ratio Metrics
| PB Ratio | 3.14 |
| PB Ratio Avg TTM | 2.91 |
| PB Ratio Avg 3Y | 2.66 |
| Current VS TTM Avg | +8.00% |
| Current VS 3Y Avg | +18.26% |
| Current VS 5Y Avg | +16.61% |
DGX Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 17.42 |
| PFCF Ratio Avg TTM | 16.14 |
| PFCF Ratio Avg 3Y | 17.30 |
| Current VS TTM Avg | +7.94% |
| Current VS 3Y Avg | +0.67% |
| Current VS 5Y Avg | +14.17% |
DGX Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.95 |
| Debt/Equity Ratio Avg TTM | 0.92 |
| Debt/Equity Ratio Avg 3Y | 0.88 |
| Current VS TTM Avg | +2.48% |
| Current VS 3Y Avg | +7.65% |
| Current VS 5Y Avg | +14.66% |
DGX PEG Ratio Metrics
| PEG Ratio | 1.43 |
| PEG Ratio Avg TTM | 4.21 |
| PEG Ratio Avg 3Y | 4.21 |
| Current VS TTM Avg | -66.03% |
| Current VS 3Y Avg | -66.03% |
| Current VS 5Y Avg | -35.07% |
DGX FCF Yield
| FCF Yield | 5.74% |
| FCF Yield Avg TTM | 6.22% |
| FCF Yield Avg 3Y | 5.76% |
| Current VS TTM Avg | -7.68% |
| Current VS 3Y Avg | -0.35% |
| Current VS 5Y Avg | -20.14% |
DGX Earnings Yield
| Earnings Yield | 4.39% |
| Earnings Yield Avg TTM | 4.59% |
| Earnings Yield Avg 3Y | 4.84% |
| Current VS TTM Avg | -4.45% |
| Current VS 3Y Avg | -9.37% |
| Current VS 5Y Avg | -33.58% |
DGX EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 18.39 |
| Ev/Ebit Ratio Avg TTM | 17.88 |
| Ev/Ebit Ratio Avg 3Y | 17.63 |
| Current VS TTM Avg | +2.87% |
| Current VS 3Y Avg | +4.31% |
| Current VS 5Y Avg | +24.95% |
DGX EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 13.98 |
| Ev/Ebitda Ratio Avg TTM | 12.92 |
| Ev/Ebitda Ratio Avg 3Y | 12.65 |
| Current VS TTM Avg | +8.18% |
| Current VS 3Y Avg | +10.51% |
| Current VS 5Y Avg | +28.88% |
DGX EV/Assets Ratio Metrics
| Ev/Assets Ratio | 1.78 |
| Ev/Assets Ratio Avg TTM | 1.68 |
| Ev/Assets Ratio Avg 3Y | 1.57 |
| Current VS TTM Avg | +5.89% |
| Current VS 3Y Avg | +13.59% |
| Current VS 5Y Avg | +12.91% |
DGX EV/Sales Ratio Metrics
| Ev/Sales Ratio | 2.63 |
| Ev/Sales Ratio Avg TTM | 2.52 |
| Ev/Sales Ratio Avg 3Y | 2.37 |
| Current VS TTM Avg | +4.36% |
| Current VS 3Y Avg | +10.98% |
| Current VS 5Y Avg | +18.37% |
DGX Current Ratio Metrics
| Current Ratio | 1.18 |
| Current Ratio Avg TTM | 1.18 |
| Current Ratio Avg 3Y | 1.15 |
| Current VS TTM Avg | +0.29% |
| Current VS 3Y Avg | +2.86% |
| Current VS 5Y Avg | -7.98% |
DGX Quick Ratio Metrics
| Quick Ratio | 1.08 |
| Quick Ratio Avg TTM | 1.08 |
| Quick Ratio Avg 3Y | 1.05 |
| Current VS TTM Avg | -0.05% |
| Current VS 3Y Avg | +2.80% |
| Current VS 5Y Avg | -8.33% |
DGX ROIC Metrics
| ROIC | 8.43% |
| ROIC Avg 3Y | 8.24% |
| ROIC Avg 5Y | 10.04% |
| Current VS 3Y Avg | +2.27% |
| Current VS 5Y Avg | -16.05% |
| Current VS 10Y Avg | -11.93% |
DGX Return on Assets Metrics
| ROA | 6.11% |
| ROA Avg TTM | 5.75% |
| ROA Avg 3Y | 6.24% |
| Current VS TTM Avg | +6.26% |
| Current VS 3Y Avg | -2.08% |
| Current VS 5Y Avg | -26.42% |
DGX Return on Equity Metrics
| ROE | 13.84% |
| ROE Avg TTM | 13.34% |
| ROE Avg 3Y | 14.07% |
| Current VS TTM Avg | +3.71% |
| Current VS 3Y Avg | -1.63% |
| Current VS 5Y Avg | -23.40% |
DGX Net Profit Margin Metrics
| Net Profit Margin | 8.70% |
| Net Profit Margin Avg TTM | 8.93% |
| Net Profit Margin Avg 3Y | 8.99% |
| Current VS TTM Avg | -2.51% |
| Current VS 3Y Avg | -3.17% |
| Current VS 5Y Avg | -4.40% |
Last Updated: Friday, June 26, 2026
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis